Studies showing arsenic activating PI3K/AKT/mTOR pathway

Arsenic CompoundTreatmentCell TypeTechnique PlatformPathway EffectTissue TypeReference
Arsenite (As 3+)1.25 μM for 72 hJB6 Cl41Cell proliferation, cell cycle, gene reporter, PI3 kinase assay, Western blotting, cyclin D1 expression assay,Activated PI3K and AKTEpidermisOuyang et al. (2006)
NaAsO20,0.25,1, 5 μM for 26 wkBEAS-2BCell proliferation, soft agar, immunoblotting, ROS detection,Activated AKT and mTORLungCarpenter et al. (2011)
AsCl310 μM 0–16 hBEAS-2BWestern blotting, ELISA, cell migrationActivated AKTLungLiu et al. (2011)
AsCl30–20 μM 6–12 hBEAS-2BWestern blotting, RT-PCR, reporter assay, cell proliferation, transformation assay, ELISAActivated AKTLungBeezhold et al. (2011)
AsCl30–20 μM of arsenic chloride for up to 20 wkBEAS-2BRT-PCR, qPCR, RNA immunoprecipitation, immunofluorescenceActivated AKTLungZhang et al. (2006)
NaAsO22.5 μM for 6 wkHBECCell migration, invasion, Western blotting, immunofluorescenceActivated AKTLungWang et al. (2012)
NaAsO20–20 μM for 6 hA375Western blotting,Activated AKTSkinLi et al. (2015)
C6AsNH6O61.0 µmol/literVascular endothelial cells male Wistar rats and C57BL/6 miceMTT, cell proliferation, migration, tube formation, xenograft, immunohistochemical staining, Western blottingActivated PI3K and AKTThoracic aortaWang et al. (2016)
NaAsO20,1,2,4,8,10 μMSV-HUC-1RT-PCR, Western blotting, ELISAActivated PI3K and AKTUreterWang (2013)
  • BEAS-2B, human bronchial epithelial cells; CLL, chronic lymphocytic leukemia; ELISA, enzyme-linked immunosorbent assay; GSH, glutathione; HBEC, human bronchial epithelial cells; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.